Atlas Trials

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

Clinical trial NCT03691051 · UNKNOWN

Trial details

NCT number
NCT03691051
Sponsor
Henan Cancer Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
HER2 Positive Metastatic Breast Cancer
Start date
2018-11-20
Primary completion
2021-04-16
Enrollment
78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.